Haemophilia A treatment preferences: a survey for patients in Germany
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study uses a survey to understand what matters most to people with haemophilia A when choosing treatments. Your answers could help doctors and researchers design better care options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with haemophilia A (with or without inhibitors).
- You live in Germany.
- You can read and understand German well enough to complete a survey.
- You are willing and able to give your consent to take part.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects real-world information on how well a personalized clotting-factor plan helps people with hemophilia A get rid of inhibitors. It may help doctors refine treatment for patients who develop antibodies that block factor therapy.
This study tests an experimental oral medication (Inno8) for people with hemophilia A. It aims to find the best dose and see how the body handles it. You may be able to join if you have mild to severe hemophilia A and are not on other preventive treatments.
This study is tracking how well Alhemo works in people with hemophilia A or B who have developed inhibitors (antibodies that block treatment). It is for patients of any age who have already started taking Alhemo as part of their regular care.
This study tests how well and how safely Octapharma’s clotting factor products (Nuwiq, Octanate, or Wilate) work in people with Hemophilia A who are newly treated or have had very few clotting factor doses. It also looks at how often side effects occur and how the treatments are used in real care.
This study looks at using long-term blood thinners (anticoagulants) in adults with severe hemophilia A, a bleeding disorder. It aims to understand if this treatment can be safe and effective for patients who may need it.
This study looks at the experiences of people with haemophilia, their caregivers, and doctors in Asia and the Pacific. The goal is to understand current care and find ways to improve it. You may be asked about your treatment and daily life.
Hear when a new Haemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.